Possible adverse reactions of Avatrombopag/Sucoxin

Avatrombopag is an oral thrombopoietin receptor agonist, mainly used to treat thrombocytopenia associated with chronic liver disease and chronic immune thrombocytopenia (ITP). Although the drug has shown good efficacy and tolerability in increasing platelets and reducing the risk of bleeding, it may still cause some adverse reactions during clinical use. Patients need to pay attention to it and use it rationally under the guidance of a doctor.

The most common adverse reactions include headache, fatigue, nausea, diarrhea, and upper respiratory tract infection, which are usually mild to moderate and can be tolerated by most patients without interrupting treatment. In addition, some patients may experience an increase in liver function indicators during medication, manifested as an increase in transaminase or bilirubin levels. Especially those with chronic liver disease or existing liver function damage should be closely monitored. Therefore, it is recommended to regularly review liver function in the initial stage of medication and during the dosage adjustment stage.

Another adverse reaction that requires caution is thrombosis. Since the mechanism of action of avatrombopag is to stimulate platelet production, if the platelet level rises too fast or exceeds the upper limit of normal, it may increase the risk of venous thrombosis or arterial thrombosis. It should be used with caution especially in patients with a history of thrombosis, liver cancer, cardiovascular disease, or long-term bed rest. Some patients may develop deep vein thrombosis or pulmonary embolism without obvious symptoms. Therefore, if symptoms such as leg swelling, chest pain, and difficulty breathing occur, they should seek medical attention immediately.

In addition, a very small number of patients experience allergic reactions, such as rash, itching or even anaphylactic shock, while taking the drug. The drug needs to be stopped immediately and emergency treatment required. There are also studies suggesting that long-term use may have an impact on the bone marrow hematopoietic environment, but the relevant data are still limited and require continued observation.

Reference materials:https://go.drugbank.com/drugs/DB11995